Detalhe da pesquisa
1.
SPINT2 is hypermethylated in both IDH1 mutated and wild-type glioblastomas, and exerts tumor suppression via reduction of c-Met activation.
J Neurooncol
; 142(3): 423-434, 2019 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-30838489
2.
18F-FDOPA PET and MRI characteristics correlate with degree of malignancy and predict survival in treatment-naïve gliomas: a cross-sectional study.
J Neurooncol
; 139(2): 399-409, 2018 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-29679199
3.
Contrast-enhancing tumor growth dynamics of preoperative, treatment-naive human glioblastoma.
Cancer
; 122(11): 1718-27, 2016 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-26998740
4.
Vision loss in glioblastoma: Disease mimicking presumed therapeutic toxicity.
Neurooncol Pract
; 5(4): 223-226, 2018 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-30402261
5.
Molecular Evolution of a Glioblastoma Controlled With Tumor Treating Fields and Concomitant Temozolomide.
Front Oncol
; 8: 451, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-30374424
6.
D-2-Hydroxyglutarate Is Necessary and Sufficient for Isocitrate Dehydrogenase 1 Mutant-Induced MIR148A Promoter Methylation.
Mol Cancer Res
; 16(6): 947-960, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29545476
7.
Phase 2 Study of Bortezomib Combined With Temozolomide and Regional Radiation Therapy for Upfront Treatment of Patients With Newly Diagnosed Glioblastoma Multiforme: Safety and Efficacy Assessment.
Int J Radiat Oncol Biol Phys
; 100(5): 1195-1203, 2018 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29722661
8.
Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy.
Neuro Oncol
; 19(3): 394-404, 2017 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27571882
9.
The MGMT promoter SNP rs16906252 is a risk factor for MGMT methylation in glioblastoma and is predictive of response to temozolomide.
Neuro Oncol
; 17(12): 1589-98, 2015 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-25910840
10.
Quantification of Nonenhancing Tumor Burden in Gliomas Using Effective T2 Maps Derived from Dual-Echo Turbo Spin-Echo MRI.
Clin Cancer Res
; 21(19): 4373-83, 2015 Oct 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-25901082